Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis
solutions company, announced today that its Cytek® Aurora™ CS
system has been selected as the “Cell Sorting Product of the Year”
in the third annual BioTech Breakthrough Awards program. This
program is conducted by BioTech Breakthrough, a leading independent
market intelligence organization that evaluates and recognizes
standout life sciences and biotechnology companies, products, and
services around the globe. This year’s program attracted more than
1,500 nominations from 12 different countries.
The Cytek Aurora CS system is the only cell
sorter on the market that offers the unique ability to combine the
advantages of Full Spectrum Profiling™ (FSP™) technology with
high-performance cell sorting. The Cytek Aurora CS system is built
on the same FSP technology as the Cytek Aurora cell analysis
system, which allows seamless transfer of assays between systems
without redesigning panels, reconfiguring detectors, or sacrificing
resolution.
FSP technology is a novel approach that detects
the full spectrum of the fluorescent probes labeled on each cell,
facilitating the resolution of the most challenging cell
populations, such as cells with high autofluorescence, low levels
of biomarker expression or rare populations – regardless of assay
size and complexity, with the ability to accurately sort
subpopulations for high-dimensional and high-complexity
applications. Combining the benefits of FSP technology with a
customizable sorting platform provides scientists with increased
flexibility in panel design, simplifies workflow with single-tube
assays, and delivers high-resolution sorting capability at the
single cell level. The Cytek Aurora CS system enables scientists to
gain a deeper understanding of complex biological systems.
“We’re thrilled to present Cytek Biosciences
with the ‘Cell Sorting Product of the Year’ award,” said Bryan
Vaughn, managing director of BioTech Breakthrough Awards. “Their
technology addresses the difficulty of sorting challenging cell
populations. The Cytek Aurora CS system is able to multiplex,
resolve and isolate even the dim and rarest populations, therefore,
scientists can now push the boundaries of their research and make
new discoveries.”
The mission of the annual BioTech Breakthrough
Awards program is to conduct the most comprehensive analysis and
evaluation of the top companies, solutions and products in the life
sciences and biotechnology industry today.
“Utilizing our powerful FSP technology, we set
out to develop a solution that can accommodate a variety of
biological and sorting conditions, while allowing researchers to
confidently and efficiently isolate populations of interest for
downstream applications,” said Wenbin Jiang, Ph.D., CEO of Cytek
Biosciences. “We are proud to accept this award from BioTech
Breakthrough, and will continue to build on our successes that
advance the next generation of cell analysis solutions.”
Please visit www.cytekbio.com for more
information.
About Cytek Biosciences,
Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading
cell analysis solutions company advancing the next generation of
cell analysis tools by delivering high-resolution, high-content and
high-sensitivity cell analysis utilizing its patented Full Spectrum
Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the
power of information within the entire spectrum of a fluorescent
signal to achieve a higher level of multiplexing with precision and
sensitivity. Cytek’s FSP platform includes its core instruments,
the Cytek Aurora™ and Northern Lights™ systems; its cell sorter,
the Cytek Aurora™ CS; the flow cytometer and imaging products under
the Amnis® and Guava® brands; and reagents, software and services
to provide a comprehensive and integrated suite of solutions for
its customers. Cytek is headquartered in Fremont, California with
offices and distribution channels across the globe. More
information about the company and its products is available at
www.cytekbio.com.
Cytek’s products are for research use only and
not for use in diagnostic procedures (other than Cytek’s Northern
Lights-CLC system and certain reagents, which are available for
clinical use in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek
Aurora, Northern Lights, Amnis and Guava are trademarks of Cytek
Biosciences, Inc.
In addition to filings with the Securities and
Exchange Commission (SEC), press releases, public conference calls
and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn
page and X (formerly Twitter) account as channels of
distribution of information about its company, products, planned
financial and other announcements, attendance at upcoming investor
and industry conferences and other matters. Such information may be
deemed material information and Cytek may use these channels to
comply with its disclosure obligations under Regulation FD.
Therefore, investors should monitor Cytek’s website, LinkedIn page,
and X account in addition to following its SEC filings, news
releases, public conference calls and webcasts.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 as
contained in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
which are subject to the “safe harbor” created by those sections.
All statements, other than statements of historical facts, may be
forward-looking statements. Forward-looking statements generally
can be identified by the use of forward-looking terminology such as
“may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negatives
of these terms or variations of them or similar terminology, but
the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include
statements regarding Cytek’s business plans, including continuing
to build on its successes that advance the next generation of cell
analysis solutions. These statements are based on management’s
current expectations, forecasts, beliefs, assumptions and
information currently available to management. These statements
also deal with future events and involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from the
information expressed or implied by these forward-looking
statements. Factors that could cause actual results to differ
materially include risks and uncertainties such as those relating
to Cytek’s ability to manage the growth and complexity of its
organization; Cytek’s ability to manage relationships with key
customers and suppliers; Cytek’s ability to retain key employees;
Cytek’s ability to continue to stay in compliance with its material
contractual obligations, applicable laws and regulations; global
economic and market conditions; competition; and Cytek’s dependence
on certain sole and single source suppliers. You should refer to
the section entitled “Risk Factors” set forth in Cytek’s most
recent Quarterly Report on Form 10-Q filed with the SEC and other
filings Cytek Biosciences makes with the SEC from time to time for
a discussion of important factors that may cause actual results to
differ materially from those expressed or implied by Cytek’s
forward-looking statements. Although Cytek believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to Cytek as of the date
hereof, and Cytek disclaims any obligation to update any
forward-looking statements provided to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing Cytek’s views as of any date subsequent to the date of
this press release.
Media Contact:Stephanie
OlsenLages & Associates(949) 453-8080stephanie@lages.com
Investor Contact:Paul
GoodsonHead of Investor RelationsCytek
Biosciencespgoodson@cytekbio.com
A photo accompanying this announcement is
available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/c3cd627b-5de3-43e7-8027-f2334ed107ea
Cytek Biosciences (NASDAQ:CTKB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Cytek Biosciences (NASDAQ:CTKB)
Gráfica de Acción Histórica
De May 2023 a May 2024